18889881171
Kalkine 0
countryflagUS

AnaptysBio Inc

Healthcare US ANAB

23.53USD
0.21(0.90%)

Last update at 2025-06-16T15:04:00Z

Day Range

22.6623.91
LowHigh

52 Week Range

16.9641.31
LowHigh

Fundamentals

  • Previous Close 23.32
  • Market Cap696.21M
  • Volume119821
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-139.44899M
  • Revenue TTM57.17M
  • Revenue Per Share TTM2.09
  • Gross Profit TTM -78.51100M
  • Diluted EPS TTM-6.05

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -128.70000M -57.79600M -19.93100M -97.48800M -61.84800M
Minority interest - - - - -
Net income -128.72400M -57.19300M -19.92000M -97.33600M -61.65600M
Selling general administrative 36.64M 21.49M 18.85M 16.09M 15.53M
Selling and marketing expenses - - - - -
Gross profit 10.29M 63.17M 75.00M 8.00M 5.00M
Reconciled depreciation 2.33M 2.09M 0.56M 0.51M 0.32M
Ebit -115.15400M -56.81400M -23.87900M -107.43200M -60.51100M
Ebitda -107.59200M -56.34600M -19.37200M -96.44700M -60.19600M
Depreciation and amortization 7.56M 0.47M 4.51M 10.98M 0.32M
Non operating income net other -18.37000M -1.40000M 3.61M 11.55M 6.78M
Operating income -115.15400M -56.81400M -23.87900M -107.43200M -66.72200M
Other operating expenses 125.44M 119.99M 98.88M 115.43M 71.72M
Interest expense 21.11M 1.45M 3.96M 1.04M 1.65M
Tax provision 0.02M 0.00000M 0.00000M -0.15200M -0.19200M
Interest income 7.55M 0.43M 3.96M 10.98M 6.68M
Net interest income -13.55800M -1.01900M 3.96M 9.94M 5.03M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.02M -0.60300M -0.01100M -0.15200M -0.19200M
Total revenue 10.29M 63.17M 75.00M 8.00M 5.00M
Total operating expenses 125.44M 119.99M 98.88M 115.43M 71.72M
Cost of revenue - - - 99.34M 56.20M
Total other income expense net -13.54600M -0.98200M 3.95M 9.94M -0.15900M
Discontinued operations - - - - -
Net income from continuing ops -128.72400M -57.79600M -19.93100M -97.33600M -61.65600M
Net income applicable to common shares -128.72400M -57.79600M -19.93100M -97.33600M -61.65600M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 452.39M 610.38M 643.07M 416.55M 435.20M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 9.08M 4.54M 4.90M 2.91M 3.51M
Total liab 364.29M 348.28M 286.64M 19.82M 30.19M
Total stockholder equity 88.10M 262.10M 356.43M 396.73M 405.01M
Deferred long term liab - - - - -
Other current liab 30.97M 21.63M 12.85M 15.26M 0.87M
Common stock 0.03M 0.03M 0.03M 0.03M 0.03M
Capital stock 0.03M 0.03M 0.03M 0.03M 0.03M
Retained earnings -614.09600M -450.47700M -321.75300M -263.95700M -244.02600M
Other liab - 304.41M 251.09M - 0.65M
Good will - - - - -
Other assets - 0.26M 0.26M 18.21M 0.14M
Cash 35.97M 71.31M 495.73M 250.46M 171.02M
Cash and equivalents - - - - -
Total current liabilities 37.44M 26.05M 16.10M 19.82M 29.54M
Current deferred revenue - - - - 10.18M
Net debt -18.15100M -51.85800M -474.77400M -250.11400M -168.77100M
Short term debt 1.78M 1.64M 1.50M 0.34M 2.25M
Short long term debt - - - - 1.38M
Short long term debt total 17.81M 19.45M 20.95M 0.34M 2.25M
Other stockholder equity 702.97M 717.80M 678.58M 660.66M 213.47M
Property plant equipment - 2.09M 2.28M 1.78M 3.02M
Total current assets 406.83M 447.20M 553.88M 396.56M 377.73M
Long term investments 27.03M 142.94M 67.10M 17.55M 54.30M
Net tangible assets - 584.33M 626.97M 396.73M 405.01M
Short term investments 354.94M 369.93M 52.37M 143.20M 203.21M
Net receivables 6.85M 1.42M 0.88M - -
Long term debt - - - - -
Inventory 0.00000M - -0.87600M - -
Accounts payable 4.70M 2.78M 1.74M 4.22M 16.24M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -0.79700M -5.24600M -0.42200M -0.00400M 0.34M
Additional paid in capital - - - - -
Common stock total equity - 0.03M 0.03M 0.03M 0.03M
Preferred stock total equity - - - - -
Retained earnings total equity - -450.47700M -321.75300M -263.95700M -244.02600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.26M 0.26M 0.26M 0.66M 1.54M
Deferred long term asset charges - - - - -
Non current assets total 45.55M 163.18M 89.19M 19.99M 57.46M
Capital lease obligations 17.81M 19.45M 20.95M 0.34M 0.87M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -394.48700M 40.19M 95.04M 132.24M -141.38800M
Change to liabilities 9.70M -4.74000M -8.87700M 14.50M 7.22M
Total cashflows from investing activities -394.84500M 38.84M 94.47M 131.43M -142.45100M
Net borrowings - - -1.37500M -7.50000M -6.87500M
Total cash from financing activities 44.02M 252.30M -0.87900M -4.49300M 223.36M
Change to operating activities -2.31800M -1.87300M 2.11M 2.35M -3.76100M
Net income -128.72400M -57.79600M -19.93100M -97.33600M -61.65600M
Change in cash -424.42100M 245.21M 79.44M 57.42M 32.41M
Begin period cash flow 495.73M 250.52M 171.08M 113.66M 81.25M
End period cash flow 71.31M 495.73M 250.52M 171.08M 113.66M
Total cash from operating activities -73.59300M -45.92000M -14.15700M -69.51700M -48.50600M
Issuance of capital stock 11.83M 2.55M 0.00000M 0.00000M 227.48M
Depreciation 2.33M 2.09M 0.56M 0.51M 0.32M
Other cashflows from investing activities - 0.01M - 132.24M -141.38800M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.54300M -0.87600M -0.87600M -0.87600M -0.87600M
Sale purchase of stock 11.83M 2.55M 0.50M 3.01M 230.27M
Other cashflows from financing activities 32.19M 249.75M 0.50M 3.01M 2.76M
Change to netincome 18.60M 1.94M 11.99M 0.68M -0.58700M
Capital expenditures 0.36M 1.37M 0.57M 0.81M 1.06M
Change receivables - - - - -
Cash flows other operating 26.16M 14.05M 13.63M 14.76M 6.20M
Exchange rate changes - - - - -
Cash and cash equivalents changes -424.42100M 245.21M 79.44M 57.42M 32.41M
Change in working capital 6.84M -7.48900M -6.77100M 16.85M 3.46M
Stock based compensation 27.36M 15.35M 11.50M 12.41M 9.96M
Other non cash items 18.60M 1.45M 0.49M 0.68M 0.65M
Free cash flow -73.95100M -47.28600M -14.72600M -70.32200M -49.56900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ANAB
AnaptysBio Inc		 0.21 0.90% 23.53 - - 12.18 8.95 5.97 -1.2991
NVO
Novo Nordisk A/S		 -2.25 2.82% 77.58 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -1.25 1.54% 79.75 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.04 0.45% 453.41 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 6.40 1.21% 535.64 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

AnaptysBio Inc

10770 Wateridge Circle, San Diego, CA, United States, 92121-5801

Key Executives

Name Title Year Born
Mr. Daniel R. Faga Interim Pres & CEO and Director 1980
Mr. Eric J. Loumeau COO & Gen. Counsel 1963
Mr. Hamza Suria M.B.A., M.Sc. Advisory 1976
Dr. Paul F. Lizzul FAAD, M.B.A., M.D., M.P.H., Ph.D. Chief Medical Officer 1975
Mr. Dennis M. Mulroy Chief Financial Officer 1955
Mr. Benjamin Stone Sr. VP of Corp. Devel. NA
Ms. Beth Mueller Sr. VP of HR NA
Dr. Martin Dahl Ph.D. Sr. VP of Research NA
Mr. Daniel R. Faga President, CEO & Director 1980
Mr. Eric J. Loumeau Chief Legal Officer 1963

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.